Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

SOPHIA GENETICS SA reports that CEO Ross Muken sold 9,838 ordinary shares to cover tax obligations related to vested restricted stock units, executed under a Rule 10b5-1 trading plan.

Summary

• Ross Muken, CEO of SOPHiA GENETICS SA, sold 9,838 ordinary shares on July 6, 2026.
• The sale was conducted to satisfy tax withholding obligations associated with the vesting of restricted stock units on July 2 and July 3, 2026.
• These transactions were executed under a pre-established Rule 10b5-1(c) trading plan, indicating they were not discretionary.
• The shares were sold at a weighted average price of $5.22, with individual sales ranging from $4.97 to $5.43.
• Following these sales, Muken beneficially owns 670,651 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves an insider sale, the clear explanation of it being for tax withholding under a pre-arranged plan mitigates negative sentiment.

Positives

• The sale was executed under a Rule 10b5-1(c) trading plan, which is designed to comply with insider trading regulations and demonstrates adherence to pre-planned financial management.
• The sale was for tax withholding purposes, a common and expected event for executives receiving stock-based compensation, rather than a discretionary divestment.

Negatives

• A portion of the insider's holdings was sold, which could be perceived negatively by the market, although the reason is for tax obligations.
• The weighted average sale price of $5.22 might indicate a price point that the insider deemed appropriate for divestment at this time.

Risks

• While the sale was part of a pre-planned trading plan for tax purposes, any significant insider selling can sometimes be misinterpreted by the market as a lack of confidence in the company's future prospects.
• The price range of sales ($4.97 to $5.43) may reflect market conditions or the insider's valuation at the time of the transactions.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on a past transaction.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1(c) trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes under Rule 10b5-1 plans are a common occurrence in the biotechnology and healthcare technology sectors, especially following significant vesting events of equity compensation. This filing indicates standard financial planning by a key executive.

Stakeholder Impact

• Shareholders: The sale is unlikely to have a significant negative impact due to its nature as a pre-planned tax event. However, any insider selling can create short-term market noise.
• Employees: No direct impact is indicated.
• Creditors: No direct impact is indicated.
• Suppliers: No direct impact is indicated.
• Customers: No direct impact is indicated.

Next Steps

• The reporting person may provide further details on specific sale prices upon written request from the issuer, security holders, or the SEC staff.

Key Dates

Keywords

SOPHIA GENETICS SA, Insider Trading, Form 4, Stock Sale, Tax Withholding, Rule 10b5-1, Restricted Stock Units, CEO, Beneficial Ownership